Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11943841 | 0.91 | LMNA (0.51) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL17058371 | 0.86 | ALDH1A1 (0.42) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL11943790 | 0.85 | ALDH1A1 (0.42) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL17058293 | 0.83 | HPGDS (0.42) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL11943792 | 0.83 | HPGDS (0.47) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL11945065 | 0.83 | ALDH1A1 (0.53) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL11945055 | 0.83 | MAPT (0.48) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL11943797 | 0.82 | SMN1; SMN2 (0.48) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL17058165 | 0.82 | POLB (0.38) | HPGDSALDH1A1SMN1; SMN2KDM4EPKM | |
| SCHEMBL17058374 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | HPGDS 558/4885ALDH1A1 2437/4885SMN1; SMN2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.